Literature DB >> 17632263

A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation.

Wing Leung1, Hyunah Ahn, Susan R Rose, Sean Phipps, Teresa Smith, Kwan Gan, Madeline O'Connor, Gregory A Hale, Kimberly A Kasow, Raymond C Barfield, Renee M Madden, Ching-Hon Pui.   

Abstract

As survivors of pediatric allogeneic hematopoietic stem cell transplantations (HSCTs) increase in number, it is increasingly important to evaluate their well-being. We conducted this prospective cohort study to evaluate the cumulative incidence and risk factors for late sequelae of HSCT. Comprehensive surveillance tests were performed annually on every participant, regardless of signs and symptoms, to obtain accurate information on the time-of-onset of each late event to allow hazard function analyses. All participants included in this report had been followed for at least 3 years after HSCT. With a median follow-up of 9 years and a current age of 18.5 years, only 20 of the 155 participants (13%) had no late sequelae; 18 survivors (12%) had 1 chronic health condition, 71 (46%) had 2-4 conditions, and 46 (30%) had 5-9 conditions. Risk factors for increasing number of chronic conditions included young age at the time of HSCT, female sex, high radiation dose, and history of chronic graft-versus-host disease. The cumulative incidence at 10 years for common late events was as follows (ordered by the median time-of-onset): osteonecrosis 13.8%, chronic renal insufficiency 26.8%, hypothyroidism 45.1%, growth hormone deficiency 31.2%, female hypogonadism 57.4%, osteopenia 47.7%, cataracts 43.4%, pulmonary dysfunction 63.2%, and male hypogonadism 20.3%. Coexistence of multiple late sequelae was common in HSCT survivors. Our findings provide a basis for more effective patient counseling, optimal surveillance, and early intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632263     DOI: 10.1097/MD.0b013e31812f864d

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  39 in total

1.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Authors:  Hiroto Inaba; Christine M Hartford; Deqing Pei; Meredith J Posner; Jie Yang; Randall T Hayden; Ashok Srinivasan; Brandon M Triplett; Jon A McCulllers; Ching-Hon Pui; Wing Leung
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

4.  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.

Authors:  Wing Leung; Dario Campana; Jie Yang; Deqing Pei; Elaine Coustan-Smith; Kwan Gan; Jeffrey E Rubnitz; John T Sandlund; Raul C Ribeiro; Ashok Srinivasan; Christine Hartford; Brandon M Triplett; Mari Dallas; Asha Pillai; Rupert Handgretinger; Joseph H Laver; Ching-Hon Pui
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

5.  Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation.

Authors:  Hiroto Inaba; Jie Yang; Sue C Kaste; Christine M Hartford; Megan S Motosue; Wassim Chemaitilly; Brandon M Triplett; David R Shook; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

6.  Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant.

Authors:  Hsiu-Ju Yen; Hesham M Eissa; Neel S Bhatt; Sujuan Huang; Matthew J Ehrhardt; Nickhill Bhakta; Kirsten K Ness; Kevin R Krull; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; I-Chan Huang
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

7.  Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency.

Authors:  Brandon M Triplett; Chong Wang; Jie Yang; Mari Dallas; Christine Hartford; Vanessa Howard; Asha Pillai; David Shook; Ashok Srinivasan; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-27       Impact factor: 5.742

8.  Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation.

Authors:  Stephanie J Lee; Travis Seaborn; Frances J Mao; Susan C Massey; Ngoc Q Luu; Mary A Schubert; Jason W Chien; Paul A Carpenter; Carina Moravec; Paul J Martin; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

9.  Clinical utility of computed tomography screening of chest, abdomen, and sinuses before hematopoietic stem cell transplantation: the St. Jude experience.

Authors:  Kimberly A Kasow; Jennifer Krueger; Deo Kumar Srivastava; Chenghong Li; Raymond Barfield; Wing Leung; Edwin M Horwitz; Renee Madden; Paul Woodard; Ishtiaq Hussain; M Beth McCarville; Rupert Handgretinger; Gregory A Hale
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

10.  The quality of life of adult survivors of childhood hematopoietic cell transplant.

Authors:  J E Sanders; P A Hoffmeister; B E Storer; F R Appelbaum; R F Storb; K L Syrjala
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.